GlassScriptPhysician profile
Piyush Raman
NPI 1558471201
$4,520.00
in general payments reported to CMS, 2019-2025
21 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $117 · 2021: $350 · 2022: $523 · 2023: $532 · 2024: $1,470 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.45 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,400.23 | 2019-2025 | |
| Abbvie INC. | $874.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $518.73 | 2020-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $398.37 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Dermavant Sciences, INC. | $285.24 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $186.00 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $148.55 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $144.40 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $131.11 | 2023-2025 | Zoryve |
| Ucb, INC. | $86.58 | 2021-2025 | Bimzelx |
| Organon LLC | $72.97 | 2025 | Vtama |
| Pfizer INC. | $60.26 | 2021-2024 | |
| Incyte Corporation | $41.49 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $35.40 | 2019 | |
| Kerecis Limited | $27.72 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.81 | 2022 | |
| Leo Pharma INC. | $21.17 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.84 | 2024 | Nuzyra |
| Amgen INC. | $15.38 | 2025 | Otezla |
| Glenmark Therapeutics INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piyush Raman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.